Under Section 506C of the Federal Food, Drug, and Cosmetic Act, companies are required to notify the FDA of a permanent discontinuance of certain drug products six months in advance, or as soon as practicable.
A generic version of the contraceptive patch is now available, and if women have questions about transitioning to this generic alternative, or to other forms of birth control, they should speak with a health care provider.” William Foster, spokesperson for Janssen Pharmaceuticals, confirmed the move in the following statement: “Janssen Pharmaceuticals has decided to discontinue its birth control patch Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) in the United States. Fast forward to the present: The manufacturer has production of the device “due to a business decision,” according to information on the Food and Drug Administration (FDA) website.
Rewind to 2002: The first transdermal contraceptive, the Ortho Evra patch, hit U.S.
